ZymoGenetics spins off of Novo Nordisk; raises $150mm
Novo Nordisk AS has spun-off its US subsidiary ZymoGenetics through the sale of $150mm worth of the unit's stock, a 35% stake, to a group of investors led by EM Warburg, Pincus & Co.
Drug Discovery Tools
- Drug Discovery Tools
- Private Placement
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com